BRCA1 and neoplasm: Rottenberg et al.18 and Hay et al.19 showed that the free‐drug combination of AZD2281 with cisplatin or carboplatin significantly reduced resistance to platinum‐based agents in BRCA1 mutated ovarian and breast cancer tumor‐bearing mice and prolonged overall survival compared with either monotherapy.